INFORMATION BROCHURE PENTAVALENT ABCDE BOTULINUM TOXOID

File: 120396_sep96_decls5_0003.txt
Page: 0003
Total Pages: 8

Subject: INFORMATION BROCHURE PENTAVALENT ABCDE BOTULINUM TOXOID         

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003203

Folder Title: INFORMATIONAL BROCHURE PENTAVALENT BOTULINUM TOXOID                                             

Document Number:          1

Folder SEQ  #:         40






       09/07,190 15: 38  1&301 663 2982         HQ USAMWC       4-4 OTSG


     SENT BY:CDC COM. CENTE.R         5-50   8 0 2  ATLANTA G'CORGIA USA@







                Since 1970, almost 10,000 injoetions of the tozoid,bav* been
                administered to recipients who wore subsequently observed for
                adverse reactions-. The rate of moderate and savors local reactions
                was 6.9% for the initial series of shots and 10.7% for booster
                shots (Table. I),.     iii addition,. there was a low incidence of
                systemic reactions (3.0%) for both tbL& initial series -at%d the
                booster shots.        The systemic rsaction were generally milct.-
                consisting of fever, tiredness, headache, and muscle pain (Table
                II).     Gyntemic reactions were often concurrent with local
                reactions,

                Moderate or severe systemic reactions and severe local reactions
                are not anticipated and should be reported by telephone to the CDC
                Drug servic&.

                Ettause-of the documented increase in-reactiona, now lots of taxoid
                were manufactured in 1971, but distribution of the original lot wait
                continued until 1981. A recent report on a very limited study on
                the reactogenicity of the now lots of . tozoid indicated that they
                are -probabiv nb less reactogenic than the previous lot (1).
                lf*ting the higher incidence of local reactions following subsequo4t
                yearly bacaters- than following initial- series sbotsf it was deeme(L
                advisable to evaluate -the need for boosters by..-@-o@ning--
                antitoxin levels and to boost only when necessary. This approach
                revealed that boosters subsequent to the first one are not
                necess*ry more frequently than at 2 year intervals and that many
ed. Prior to 1974, yearly boosters
                were routinely given.
                Xoderate local roactioni     include arythem, edema and induratim.
                all such reactions rsach a peak in 24,hours, then gradually subside
                and should be gone at 48 or at the most 72 hours. When a moderate
                local reaction occurs, reduction of the doze of each Oubsoquent
                injections to 0.2$ Ml has been shown to *Iloviate the reaction
                without impairing the antitoxin response.
                Rarely, an individual may have a reaction- characterized by a deep,
                painless, ncuizlflw=tory subcutaneous induration that may persist
                for 3 to 4 weeks.         These rarsly measure more then 2 to 3
                centimeters in diameter and are absorbed without residue.

Document 8 f:/Week-36/BX003203/INFORMATIONAL BROCHURE PENTAVALENT BOTULINUM TOXOID/information brochure pentavalent abcde botulinum:1108961508426
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = INFORMATIONAL BROCHURE PENTAVALENT BOTULINUM TOXOID
Folder Seq # = 40
Subject = INFORMATION BROCHURE PENTAVALENT ABCDE BOTULINUM
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 08-NOV-1996